Cerity Partners’s Organogenesis Holdings ORGO Stock Holding History

Cerity Partners’s Portfolio ORGO Stock Details ORGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$149K	Sell	62,909 -3,670	-6%	-$12.7K	﹤0.01%	2951
2025 Q4	$345K	Sell	66,579 -4,183	-6%	-$20.3K	﹤0.01%	2322
2025 Q3	$299K	Buy	70,762 +381	+0.5%	+$1.77K	﹤0.01%	2285
2025 Q2	$258K	Sell	70,381 -4,499	-6%	-$16.8K	﹤0.01%	2231
2025 Q1	$323K	Buy	74,880 +24,362	+48%	+$98.4K	﹤0.01%	1989
2024 Q4	$161K	Sell	50,518 -193	-0.4%	-$648	﹤0.01%	2275
2024 Q3	$145K	Buy	50,711 +20,757	+69%	+$58.2K	﹤0.01%	2381
2024 Q2	$83.9K	Buy	+29,954	New	+$80.4K	﹤0.01%	2131

Other funds holding ORGO

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cerity Partners's ORGO Position: Q1 2026 in Review

Cerity Partners reduced its Organogenesis Holdings (ORGO) stake by 5.5% in Q1 2026, selling an estimated $12.7K and leaving 62,909 shares worth $149K. The position accounts for ﹤0.01% of the portfolio, ranked #2951.

Cerity Partners first reported a position in ORGO in Q2 2024 and has held it in 8 quarters since. The position peaked at $345K in Q4 2025. 121 funds tracked by Wall St. Rank hold ORGO as of Q1 2026.

Cerity Partners held 62,909 shares of Organogenesis Holdings worth $149K as of Q1 2026.
Cerity Partners sold 3,670 Organogenesis Holdings shares in Q1 2026, an estimated $12.7K.
Organogenesis Holdings made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2951 holding.
Cerity Partners first reported a position in Organogenesis Holdings in Q2 2024 and has held it in 8 quarters since.
Cerity Partners's Organogenesis Holdings position peaked at $345K in Q4 2025.
121 funds tracked by Wall St. Rank held Organogenesis Holdings as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.